[go: up one dir, main page]

CN1367697A - Therapeutical method for improving cognition - Google Patents

Therapeutical method for improving cognition Download PDF

Info

Publication number
CN1367697A
CN1367697A CN99812184A CN99812184A CN1367697A CN 1367697 A CN1367697 A CN 1367697A CN 99812184 A CN99812184 A CN 99812184A CN 99812184 A CN99812184 A CN 99812184A CN 1367697 A CN1367697 A CN 1367697A
Authority
CN
China
Prior art keywords
atypical antipsychotic
acetylcholinesterase inhibitor
patients
alzheimer
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99812184A
Other languages
Chinese (zh)
Inventor
P·L·I·德尼斯
W·L·J·帕里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1367697A publication Critical patent/CN1367697A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention is concerned with pharmaceutical compositions comprising a carrier and as first active ingredient an atypical antipsychotic agent (I) and as second active ingredient an acetylcholinesterase inhibitor (II), each in an amount producing a therapeutically beneficial effect in patients suffering from psychosis, or Alzheimer's disease or related dementias. Said therapeutically beneficial effect can be a synergistic effect on the cognitive functioning of patients suffering from Alzheimer's disease or related dementias or the prevention of the further deterioration of cognition in said patients, or the reduction of adverse effects associated with the one of the active ingredients by the other of the active ingredients.

Description

改善认识的疗法Cognitive Therapy

本发明涉及药用组合物，所述药用组合物包含一种载体和作为第一有效成分的非典型抗精神病药物(I)和作为第二有效成分的乙酰胆碱酯酶抑制剂(II)，每种有效成分的量在患有精神病或早老性痴呆或相关痴呆的患者中产生有益治疗效应。所述有益治疗效应可以是对早老性痴呆或相关痴呆患者的认识功能的协同作用，或是防止所述患者认识的进一步损害，或是与其中一种所述有效成分相关的有害作用因另一种所述有效成分而减少。The present invention relates to a pharmaceutical composition comprising a carrier and an atypical antipsychotic (I) as a first active ingredient and an acetylcholinesterase inhibitor (II) as a second active ingredient, each An amount of the active ingredient to produce a beneficial therapeutic effect in patients suffering from psychosis or Alzheimer's or related dementias. Said beneficial therapeutic effect may be a synergistic effect on cognitive function in patients with Alzheimer's disease or related dementias, or prevention of further impairment of cognition in said patients, or detrimental effects associated with one of said active ingredients due to the other. The active ingredients are reduced.

特别关注的是应用非典型抗精神病药物(I)来制备药物，所述药物用于减小早老性痴呆或相关痴呆患者中与乙酰胆碱酯酶抑制剂(II)有关的有害作用，例如恶心、呕吐、出汗、坐立不安和失眠。尤其关注应用非典型抗精神病药物(I)来制备药物，所述药物用于改善患有早老性痴呆或相关痴呆、同时用乙酰胆碱酯酶抑制剂(II)治疗的患者的睡眠。Of particular interest is the use of atypical antipsychotics (I) for the preparation of medicaments for reducing the deleterious effects associated with acetylcholinesterase inhibitors (II), such as nausea, vomiting, in patients with Alzheimer's or related dementias , sweating, restlessness and insomnia. Particular attention is paid to the use of atypical antipsychotics (I) for the preparation of medicaments for improving sleep in patients with Alzheimer's disease or related dementias who are concurrently treated with acetylcholinesterase inhibitors (II).

本发明涉及药用组合物，所述药用组合物包含一种载体和作为第一有效成分的非典型抗精神病药物(I)和作为第二有效成分的乙酰胆碱酯酶抑制剂(II)，每种有效成分的量在患有精神病或早老性痴呆或相关痴呆的患者中产生有益治疗效应。所述有益治疗效应可以是对早老性痴呆或相关痴呆的患者的认识功能的协同作用，或是防止所述患者认识的进一步损害，或是与其中一种所述有效成分相关的有害作用因另一种所述有效成分而减少。The present invention relates to a pharmaceutical composition comprising a carrier and an atypical antipsychotic (I) as a first active ingredient and an acetylcholinesterase inhibitor (II) as a second active ingredient, each An amount of the active ingredient to produce a beneficial therapeutic effect in patients suffering from psychosis or Alzheimer's or related dementias. The beneficial therapeutic effect may be a synergistic effect on cognitive function in patients with Alzheimer's disease or related dementias, or prevention of further impairment of cognition in said patients, or detrimental effects associated with one of the active ingredients due to another reduced by one of the active ingredients.

所述非典型抗精神病药物(I)选自利培酮、9-羟基利培酮或其C10- 20链烷酸酯、奥氮平、quetiapine、伊潘立酮或ziprasidone，而所述乙酰胆碱酯酶抑制剂(II)选自加兰他敏、rivastigmine或donepezil；或任一上述药物的有治疗活性的酸加成盐形式。所述盐包括有效成分(I)和(II)能够与合适酸形成的盐形式，所述合适酸例如无机酸，诸如氢卤酸，例如盐酸或氢溴酸；硫酸；硝酸；磷酸等酸；或有机酸例如乙酸、丙酸、羟基乙酸、乳酸、丙酮酸、草酸、丙二酸、琥珀酸、马来酸、富马酸、苹果酸、酒石酸、柠檬酸、甲磺酸、乙磺酸、苯磺酸、对甲苯磺酸、环己氨磺酸、水杨酸、对氨基水杨酸、扑酸等酸。例如，可以方便地以(1∶1)氢溴酸盐形式使用加兰他敏。The atypical antipsychotic (I) is selected from risperidone, 9-hydroxy risperidone or its C 10-20 alkanoate, olanzapine, quetiapine, iloperidone or ziprasidone, and the acetylcholine The esterase inhibitor (II) is selected from galantamine, rivastigmine or donepezil; or a therapeutically active acid addition salt form of any of the foregoing. Said salts include the salt forms that the active ingredients (I) and (II) can form with suitable acids, such as inorganic acids, such as hydrohalic acids, such as hydrochloric acid or hydrobromic acid; sulfuric acid; nitric acid; phosphoric acid and the like; Or organic acids such as acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, Benzenesulfonic acid, p-toluenesulfonic acid, cyclamate, salicylic acid, p-aminosalicylic acid, pamoic acid and other acids. For example, galantamine may conveniently be used in the (1:1) hydrobromide salt form.

C10-20链烷酸选自癸酸、十一烷酸、十二烷酸(月桂酸)、十三烷酸、十四烷酸(肉豆蔻酸)、十五烷酸、十六烷酸(棕榈酸)、十七烷酸、十八烷酸(硬脂酸)、十九烷酸和二十烷酸。由于它们的水溶性有限，因此普遍认为必须将所述酯悬浮于油中。从药代动力学以及耐受性的观点来看，发现具有C15(十五烷基)链并且与此相应的有效成分是9-羟基利培酮棕榈酸酯的酯是优越的酯。C 10-20 alkanoic acid selected from capric acid, undecanoic acid, dodecanoic acid (lauric acid), tridecanoic acid, myristic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid, octadecanoic acid (stearic acid), nonadecanoic acid and eicosanoic acid. Due to their limited water solubility, it is generally believed that the esters must be suspended in oil. From the viewpoints of pharmacokinetics and tolerability, an ester having a C15 (pentadecyl) chain and corresponding to which the active ingredient is 9-hydroxyrisperidone palmitate was found to be a superior ester.

每种所述有效成分的量最好等于或低于采用所述有效成分的单一疗法中的许可量。The amount of each of said active ingredients is preferably equal to or lower than the allowable amount in monotherapy using said active ingredients.

最优选这样的组合物，其中所述非典型抗精神病药物(I)为利培酮，而所述乙酰胆碱酯酶抑制剂(II)为加兰他敏，特别是以加兰他敏氢溴酸盐的形式。在所述组合物中，每种剂型的利培酮的量为0.5、1、2、4或6mg，而加兰他敏(作为主药)的量为8、16、24或32mg。Most preferred is a composition wherein the atypical antipsychotic (I) is risperidone and the acetylcholinesterase inhibitor (II) is galantamine, in particular galantamine hydrobromide salt form. In the composition, the amount of risperidone in each dosage form is 0.5, 1, 2, 4 or 6 mg, and the amount of galantamine (as the main drug) is 8, 16, 24 or 32 mg.

本发明也涉及含有作为第一有效成分的非典型抗精神病药物(I)和作为第二有效成分的乙酰胆碱酯酶抑制剂(II)作为联合制剂的制品，所述联合制剂用于同时、分开或顺序地用于治疗患有精神病、早老性痴呆或相关痴呆的患者。The present invention also relates to preparations comprising an atypical antipsychotic (I) as a first active ingredient and an acetylcholinesterase inhibitor (II) as a second active ingredient as a combined preparation for simultaneous, separate or Sequentially for the treatment of patients with psychosis, Alzheimer's disease or related dementias.

本发明也涉及应用乙酰胆碱酯酶抑制剂(II)来制备在精神病患者中增强非典型抗精神病药物(I)对认识效应的药物。The present invention also relates to the use of acetylcholinesterase inhibitors (II) for the preparation of medicaments that enhance the cognitive effects of atypical antipsychotics (I) in psychotic patients.

相反，本发明也涉及应用非典型抗精神病药物(I)来制备在患有早老性痴呆或相关痴呆的患者中增强乙酰胆碱酯酶抑制剂(II)对认识效应的药物。In contrast, the present invention also relates to the use of atypical antipsychotics (I) for the preparation of medicaments that enhance the cognitive effects of acetylcholinesterase inhibitors (II) in patients with Alzheimer's or related dementias.

另外，本发明涉及应用非典型抗精神病药物(I)来制备在患有早老性痴呆或相关痴呆的患者中减小与乙酰胆碱酯酶抑制剂(II)相关的有害作用的药物。所述有害作用可以是恶心、呕吐、出汗、坐立不安或失眠。尤其关注的是应用非典型抗精神病药物(I)来制备在患者早老性痴呆或相关痴呆、同时用乙酰胆碱酯酶抑制剂(II)治疗的患者中改善睡眠的药物。In addition, the present invention relates to the use of atypical antipsychotics (I) for the preparation of medicaments that reduce the deleterious effects associated with acetylcholinesterase inhibitors (II) in patients with Alzheimer's or related dementias. The adverse effect may be nausea, vomiting, sweating, restlessness or insomnia. Of particular interest is the use of atypical antipsychotics (I) for the preparation of sleep-improving medicaments in patients with Alzheimer's disease or related dementias who are concurrently treated with acetylcholinesterase inhibitors (II).

最后，本发明涉及应用乙酰胆碱酯酶抑制剂(II)来制备在精神病患者中减小与非典型抗精神病药物(I)相关的有害作用的药物。所述有害作用可以是锥体束外综合征或迟发性运动障碍。Finally, the present invention relates to the use of acetylcholinesterase inhibitors (II) for the preparation of medicaments that reduce the deleterious effects associated with atypical antipsychotics (I) in psychotic patients. The adverse effect may be extrapyramidal syndrome or tardive dyskinesia.

在所有前述应用中，所述非典型抗精神病药物(I)最好是利培酮，而所述乙酰胆碱酯酶抑制剂(II)最好是加兰他敏，特别是其(1∶1)氢溴酸盐。In all the aforementioned applications, the atypical antipsychotic (I) is preferably risperidone, and the acetylcholinesterase inhibitor (II) is preferably galantamine, especially its (1:1) hydrobromide.

Claims (14)

1.药用组合物，其包含一种载体和作为第一有效成分的非典型抗精神病药物(I)和作为第二有效成分的乙酰胆碱酯酶抑制剂(II)，每种有效成分的量在患有精神病或早老性痴呆或相关痴呆的患者中产生有益治疗效应。1. A pharmaceutical composition comprising a carrier and an atypical antipsychotic (I) as the first active ingredient and an acetylcholinesterase inhibitor (II) as the second active ingredient, the amount of each active ingredient being Beneficial therapeutic effects in patients with psychosis or Alzheimer's or related dementias. 2.根据权利要求1的组合物，其中所述有益治疗效应是对早老性痴呆或相关痴呆患者的认识功能的协同作用，或是防止所述患者认识的进一步损害，或是与其中一种所述有效成分相关的有害作用因另一种所述有效成分而减少。2. The composition according to claim 1, wherein said beneficial therapeutic effect is a synergistic effect on cognitive function in patients with Alzheimer's disease or related dementias, or prevents further impairment of cognition in said patients, or is combined with one of the A detrimental effect associated with one of the active ingredients is reduced by another of the active ingredients. 3.根据权利要求1的组合物，其中所述非典型抗精神病药物(I)选自利培酮、9-羟基利培酮或其C10-20链烷酸酯、奥氮平、quetiapine、伊潘立酮或ziprasidone，而所述乙酰胆碱酯酶抑制剂(II)选自加兰他敏、rivastigmine或donepezil。3. The composition according to claim 1, wherein the atypical antipsychotic (I) is selected from the group consisting of risperidone, 9-hydroxy risperidone or its C 10-20 alkanoate, olanzapine, quetiapine, iloperidone or ziprasidone, and the acetylcholinesterase inhibitor (II) is selected from galantamine, rivastigmine or donepezil. 4.根据权利要求3的组合物，其中每种所述有效成分的量等于或低于采用所述有效成分的单一疗法中的许可量。4. The composition according to claim 3, wherein the amount of each of said active ingredients is equal to or lower than the permitted amount in monotherapy with said active ingredients. 5.根据权利要求3的组合物，其中所述非典型抗精神病药物(I)为利培酮，而所述乙酰胆碱酯酶抑制剂(II)为加兰他敏。5. The composition according to claim 3, wherein the atypical antipsychotic (I) is risperidone and the acetylcholinesterase inhibitor (II) is galantamine. 6.根据权利要求5的组合物，其中每种剂型的利培酮的量为0.5、1、2、4或6mg，而加兰他敏(作为主药)的量为8、16、24或32mg。6. The composition according to claim 5, wherein the amount of risperidone in each dosage form is 0.5, 1, 2, 4 or 6 mg, and the amount of galantamine (as main drug) is 8, 16, 24 or 32mg. 7.含有作为第一有效成分的非典型抗精神病药物(I)和作为第二有效成分的乙酰胆碱酯酶抑制剂(II)作为联合制剂的制品，所述联合制剂用于同时、分开或顺序地用于治疗患有精神病、早老性痴呆或相关痴呆的患者。7. A product containing an atypical antipsychotic drug (I) as a first active ingredient and an acetylcholinesterase inhibitor (II) as a second active ingredient as a combined preparation for simultaneous, separate or sequential For the treatment of patients with psychosis, Alzheimer's disease or related dementias. 8.乙酰胆碱酯酶抑制剂(II)的应用，用于制备在精神病患者中增强非典型抗精神病药物(I)对认识效应的药物。8. Use of the acetylcholinesterase inhibitor (II) for the preparation of a medicament for enhancing the cognition effect of the atypical antipsychotic drug (I) in psychotic patients. 9.非典型抗精神病药物(I)的应用，用于制备在患有早老性痴呆或相关痴呆的患者中增强乙酰胆碱酯酶抑制剂(II)对认识效应的药物。9. Use of an atypical antipsychotic (I) for the preparation of a medicament for enhancing the cognition effect of an acetylcholinesterase inhibitor (II) in a patient suffering from Alzheimer's disease or related dementias. 10.非典型抗精神病药物(I)的应用，用于制备在患有早老性痴呆或相关痴呆的患者中减小与乙酰胆碱酯酶抑制剂(II)相关的有害作用的药物。10. Use of an atypical antipsychotic (I) for the manufacture of a medicament for reducing the deleterious effects associated with an acetylcholinesterase inhibitor (II) in a patient suffering from Alzheimer's disease or related dementias. 11.根据权利要求10的应用，其中所述有害作用可以是恶心、呕吐、出汗、坐立不安或失眠。11. Use according to claim 10, wherein said adverse effect may be nausea, vomiting, sweating, restlessness or insomnia. 12.乙酰胆碱酯酶抑制剂(II)的应用，用于制备在精神病患者中减小与非典型抗精神病药物(I)相关的有害作用的药物。12. Use of an acetylcholinesterase inhibitor (II) for the manufacture of a medicament for reducing the deleterious effects associated with atypical antipsychotic drugs (I) in psychotic patients. 13.根据权利要求12的应用，其中所述有害作用是锥体束外综合征或迟发性运动障碍。13. Use according to claim 12, wherein the adverse effect is extrapyramidal syndrome or tardive dyskinesia. 14.根据权利要求8-13中任一项的应用，其中所述非典型抗精神病药物(I)为利培酮，而所述乙酰胆碱酯酶抑制剂(II)为加兰他敏。14. The use according to any one of claims 8-13, wherein the atypical antipsychotic (I) is risperidone, and the acetylcholinesterase inhibitor (II) is galantamine.
CN99812184A 1998-10-16 1999-10-12 Therapeutical method for improving cognition Pending CN1367697A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16
EP98203454.8 1998-10-16

Publications (1)

Publication Number Publication Date
CN1367697A true CN1367697A (en) 2002-09-04

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99812184A Pending CN1367697A (en) 1998-10-16 1999-10-12 Therapeutical method for improving cognition

Country Status (20)

Country Link
EP (1) EP1121131A2 (en)
JP (1) JP2002527469A (en)
KR (1) KR20010072878A (en)
CN (1) CN1367697A (en)
AU (1) AU6472799A (en)
BG (1) BG105302A (en)
BR (1) BR9914419A (en)
CA (1) CA2345767A1 (en)
EE (1) EE200100136A (en)
HK (1) HK1039745A1 (en)
HR (1) HRP20010262A2 (en)
HU (1) HUP0103781A3 (en)
ID (1) ID28441A (en)
IL (1) IL142588A0 (en)
NO (1) NO20011403L (en)
PL (1) PL348107A1 (en)
SK (1) SK4592001A3 (en)
TR (1) TR200101082T2 (en)
WO (1) WO2000023057A2 (en)
ZA (1) ZA200103081B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
CA2463158C (en) 2001-10-30 2013-07-30 Novartis Ag Depot formulations of iloperidone and a star polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
WO2004084905A2 (en) * 2003-03-24 2004-10-07 University Of Florida Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
EP1824848A1 (en) * 2004-12-10 2007-08-29 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
MX2007008642A (en) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias.
CN102905532A (en) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 Methods and compositions for improving cognitive function
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105142623A (en) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 Methods and compositions for improving cognitive function
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0584185T3 (en) * 1991-05-14 2000-02-07 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
JP4640888B2 (en) * 1997-08-11 2011-03-02 ザ ユニヴァーシティー オブ サウス フロリダ Nicotine antagonists for neuropsychiatric disorders
DE69936848T2 (en) * 1998-04-14 2008-05-15 The General Hospital Corp., Boston USE OF D-SERIN OR D-ALANINE FOR THE TREATMENT OF SCHIZOPHRENIA

Also Published As

Publication number Publication date
BR9914419A (en) 2001-06-26
NO20011403D0 (en) 2001-03-20
CA2345767A1 (en) 2000-04-27
SK4592001A3 (en) 2001-12-03
ID28441A (en) 2001-05-24
NO20011403L (en) 2001-03-20
PL348107A1 (en) 2002-05-06
EP1121131A2 (en) 2001-08-08
BG105302A (en) 2001-11-30
KR20010072878A (en) 2001-07-31
HUP0103781A2 (en) 2002-03-28
WO2000023057A2 (en) 2000-04-27
WO2000023057A3 (en) 2000-07-27
AU6472799A (en) 2000-05-08
JP2002527469A (en) 2002-08-27
IL142588A0 (en) 2002-03-10
TR200101082T2 (en) 2001-09-21
HK1039745A1 (en) 2002-05-10
ZA200103081B (en) 2002-07-12
HUP0103781A3 (en) 2003-09-29
EE200100136A (en) 2002-06-17
HRP20010262A2 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
CN1367697A (en) Therapeutical method for improving cognition
US9782403B2 (en) Treating sexual desire disorders with flibanserin
US6444665B1 (en) Method for treating pain
EP2727590B1 (en) Compositions for treating centrally mediated nausea and vomiting
MX2013001345A (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1 '-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain.
CA2608713A1 (en) Method for the treatment of sexual dysfunctions due to medical conditions
WO2022183029A1 (en) Methods and compositions for treating agitation
WO2011120281A1 (en) Use of l-oxiracetam in manufacture of medicaments for preventing or treating cognitive dysfunction
JP2003521462A (en) Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in men
CN1317030C (en) Treatment of Alzheimer's disease with moderate doses of LHRH antagonists
JP2004505036A5 (en)
AU2020377451B2 (en) Oral formulation of X842
KR100708560B1 (en) Oral Disintegrating Compositions Including Mirtazapine
JP2012500248A (en) Treatment of anxiety disorder
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
KR102222271B1 (en) Solubilized composition of fexofenadine
EP0671908B1 (en) Pharmaceutical compositions comprising 5-ht 1? receptor agonists and absorption enhancers
US20090124606A1 (en) Composition for Treatment of Psychosis
WO2025128666A1 (en) Combination of latrepirdine and a pharmacokinetic stabilizer
WO2002056869A2 (en) Method for treating sexual disorders
NZ788973B2 (en) Treating behavioral and psychological symptoms in dementia patients
Binns et al. A review of the law on second medical use patent claims: Have the English Courts gone too far in restricting second medical use claims?
WO2005058878A1 (en) Preventive and/or remedy for dysmenorrhea
AU2003259464A1 (en) Use of a quinazoline derivative for treating lower urinary tract symptoms

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication